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Abstract
One of the major challenges in rheumatology is to overcome the
classification criteria that previously defined systemic lupus
erythematosis, since the heterogeneity of the disease(s) appears to
represent a complexity that probably substantially contributed to
the failure of a number of recent trials. For those engaged in clinical
trials, validated disease activity biomarkers that respond rapidly to
treatment and are predictive of clinical response would greatly
facilitate early decision-making around futility and dose selection.
Likewise, use of validated patient stratification biomarkers possibly
in conjunction with autoantibody profiles and disease manifes-
tations will result in the recruitment of more homogeneous patient
populations during later stage clinical studies, thereby decreasing
size, costs, and risks in pivotal studies.
Challenge of lupus for drug development
Systemic lupus erythematosis (SLE) is perhaps the most
clinically and serologically diverse of the autoimmune diseases.
The current American College of Rheumatology classification
lists 11 criteria for diagnosis of lupus, of which a patient must
meet four [1]. The heterogeneity of the patient population
results in significant challenges not only in classifying disease
activity but also for establishment of therapeutic response to
new drug candidates and therapeutic strategies.
Outcome measures used in clinical trials currently rely on one
(or more) of several disease activity indices – the Systemic
Lupus Erythematosis Disease Activity Index (SLEDAI), the
Systemic Lupus Activity Measure, the British Isles Lupus
Assessment Group (BILAG), the European Consensus
Lupus Activity Measure – and their derivatives. These tools
vary in their sensitivities to response, however, dependent
upon differential organ involvement and physician assess-
ments [2,3]. Current draft US Food and Drug Administration
guidance recommends the use of the BILAG, although the
guidance does not rule out the use of other disease activity
indices [4]. US Food and Drug Administration guidance on
the development of lupus drugs has not yet been formalized,
however, despite issuing the draft guidance in 2005. This
lack of accepted clinical endpoints makes standardization of
study results difficult, and results in significant difficulties for
the successful performance of a clinical trial for novel
therapeutics for lupus.
In part because of the varied usage of disease activity indices,
because of the nature of a flaring disease, and because of
associated high placebo response rates, there is considerable
interest in the identification and validation of biomarkers for
lupus. Physicians, patients, and clinical drug development
groups seek biomarkers that more precisely reflect the level of
lupus disease activity, are predictive of impending flares, and
are associated with or predictive of clinical response to
therapeutic intervention. The US Food and Drug Adminis-
tration has in fact acknowledged the potential utility of
validated disease activity biomarkers in its guidance document
for lupus development, indicating its willingness to evaluate
‘… evidence that the proposed surrogate is reasonably likely
to predict clinical benefit’ as part of a registration package for
lupus nephritis [4]. Moreover, the use of certain biomarkers
may provide diagnostic benefit by defining subsets of a
disease that may have a distinct response profile to one or
another drug. The inclusion of a definition of the patient’s
immunological signature as part of the lupus classification
criteria could aid in evaluation of novel therapeutics, and
ultimately in treatment decision-making.
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While many cross-sectional studies have identified a plethora
of biomarkers that are associated with lupus (specifically or
not), there is a significant lack of information from longitudinal
and interventional studies that validate the utility of any
biomarker for monitoring disease activity or clinical response.
This lack of reliable, specific biomarkers for SLE not only
hampers precise assessment of disease activity and prompt
identification of patients at risk for flares and organ damage,
but also impedes the accurate evaluation of responses to
treatment [5]. Recent advances in biomarker discovery for
lupus, however, are providing new hope that a useful
biomarker index can be developed for diagnostic as well as
prognostic and response predictors.
Lupus disease activity biomarkers: value for
drug development
The pharmaceutical industry realized the unmet medical
need for new therapeutics in lupus and has made a
considerable investment in bringing new candidates to the
clinic. The result of this investment is that there are at least
15 compounds currently in clinical trials [6] with a wide
variety of different mechanisms of action. There is therefore
considerable incentive to identify biomarkers that will have
impact across the broad lupus portfolio, or alternatively
define unique SLE subsets that may require and respond to
different therapies.
In part because of the challenges around the use of the
SLEDAI or the BILAG in clinical trials, pharmaceutical
companies have focused phase II proof-of-concept clinical
trials on lupus nephritis, where laboratory measurements of
proteinuria or the glomerular filtration rate provide objective
measurements of renal disease. These designs typically call
for 6-month to 12-month clinical endpoint analyses of renal
response (if not even longer, as could be concluded from the
recent Rituximab clinical trial in lupus nephritis (LUNAR)).
Because of increased competition in the lupus field, this
patient population will be increasingly difficult to recruit – as a
result, the expected length of the proof-of-concept study may
be upwards of 2 years or more. Validated disease activity
biomarkers that respond rapidly to treatment and are
predictive of clinical response at later time points could greatly
facilitate early decision-making around futility and dose
selection, thereby shortening potentially lengthy proof-of-
concept studies. Furthermore, such biomarkers would
enhance the development of adaptive trial designs, something
not currently possible in lupus nephritis trials, further
streamlining the clinical trial process.
An additional advantage to developing a well-validated
biomarker toolbox will be the potential to identify patients
during early phase studies who are likely to respond to the
treatment being tested and who have a higher likelihood to
achieve a major response or even remission. Such patient
stratification biomarkers can result in the recruitment of a
more homogeneous patient population during later stage
clinical studies with the promise of decreasing size, costs,
and risks in pivotal registration studies.
New approaches to lupus disease activity
biomarkers
Complement levels and anti-dsDNA antibodies are classic
biomarkers of lupus disease activity that have been shown in
some, but not all, studies to be predictors of outcome in
lupus nephritis studies [7]. However, to fully capture the
multiple clinical manifestations of lupus, developing new
strategies that rely on a panel of the most reliable biomarkers
will be necessary. Given the heterogeneity of lupus, it is
unlikely that a single biomarker will be sufficient for predicting
clinical response. The simultaneous collection of multiple
biomarkers (cellular, serological and mRNA transcripts)
would therefore allow for mathematical modeling in
comparison with the SELENA-SLEDAI and the BILAG 2000
disease activity indices leading to generation of a testable
composite biomarker score for further studies in lupus.
Because of this unmet need, the interest in identifying novel
lupus disease activity biomarkers has been remarkable and
many potential new indicators of lupus activity have been
recently uncovered. Many of these novel biomarkers are only
now beginning to be evaluated in clinical settings, however,
and none has as yet been qualified as a biomarker that can
predict clinical outcomes.
Autoantibody profiles
A number of previous studies reported that SLE patients can
be dissected based on their autoantibody profile and associa-
ted clinical organ manifestations, but they are also strikingly
influenced by the genetic background [8]. In a recent multi-
variate analysis, Northern European ancestry was significantly
associated with photosensitivity (odds ratio = 1.64) and
discoid rash (odds ratio = 1.93), while having a protective
effect against anticardiolipin autoantibodies (odds ratio =
0.46) and anti-dsDNA autoantibodies (odds ratio = 0.67).
Earlier studies had already suggested that the heterogeneity
of SLE patients can be presented more homogeneously [9],
with anti-RO (SS-A) production related to the HLA-DQ1/
DQ2 heterozygotes, anti-La (SS-B) related to HLA-B8 and
HLA-DR3, and anti-nuclear RNP (Sm) related to HLA-DR4.
While lymphopenia was associated significantly with anti-Ro
(SS-A) and, secondarily, with anti-single-stranded DNA, lupus
nephritis was inversely associated with anti-La (SS-B) and
associated with anti-dsDNA. It has been repeatedly shown
that anti-dsDNA, single anti-Ro antibodies as well as Sm
antibodies [10] are associated with lupus nephritis, and in
part with central nervous system (CNS) lupus, whereas com-
bined anti-Ro/La antibodies are associated with secondary
Sjögren’s syndrome and photosensitivity, absence of lupus
nephritis and severe CNS involvement. Moreover, anti-
ribosomal P antibodies are clearly associated with CNS lupus
[11], and anticardiolipin antibodies mark patients with throm-
botic events as well as thrombocytopenia [12], serving asreliable identifiers of these clinical presentations. In a very
instructive study, the occurrence of anti-U1RNP/Sm
antibodies occurred early on and prior to the disease onset
as well as at different times from other autoantibodies [13].
These data indicate that genetic background, including HLA
class II, is important for the induction of certain auto-
antibodies that contribute to the clinical heterogeneity and
variation in disease outcomes among SLE patients. The
established associations of autoantibody profiles with clinical
subtypes may at least require consideration in the design of
SLE trials for defining stricter outcome criteria.
The interferon signature
One of the most promising lupus disease activity biomarkers
to be identified in recent years is the so-called IFN signature.
Increased levels of IFNα were first reported in lupus patients
30 years ago [14]. Twenty years later, seminal work from Lars
Rönnblom’s group reported the findings that serum from
lupus patients contained an IFN-inducing factor and that
immune complexes of anti-dsDNA antibodies and DNA could
induce IFNα production in normal peripheral blood
mononuclear cells [15,16]. Blanco and colleagues expanded
this finding by demonstrating that IFNα present in the serum
of lupus patients could induce the differentiation of peripheral
blood monocytes into dendritic cells [17]. That dysregulation
of IFNα production in lupus patients could have a global
effect was realized with the advent of transcriptional profiling
of peripheral blood mononuclear cells from lupus patients.
Gene expression profiling of lupus blood by Baechler and
colleagues first demonstrated the upregulation of a group of
IFN-stimulated genes in lupus patients [18].
This gene signature is characterized by the highly co-
ordinated upregulation of type I IFN-inducible inflammatory
cytokines, chemokines, and other genes whose expression
levels are closely correlated with clinical and laboratory
measures of SLE disease activity. At least seven separate
published studies have now validated the presence of this
signature in the peripheral blood of lupus patients [18-24].
Although some variation exists in the gene signatures identi-
fied in these different studies, some common markers can be
found – including Mx1, IFIT1, IFIT4, OASL, Ly6E, and
PLSCR1. Because of patient-to-patient variation in
expression levels of individual genes, it has been useful to
derive a cumulative IFN-response gene score based upon the
sum of the differences in the expression levels of each gene
in the patient compared with a healthy donor group. Such a
composite score can therefore decrease variability and
potentially be more indicative of real changes in disease
activity. This approach, however, requires each laboratory to
develop its own unique panel of genes and validate the assay
with a population of healthy controls and lupus patients.
Standardization of an IFN gene signature profile amongst
investigators would help significantly for comparing results
between studies.
The correlation of the IFN signature with more traditional
measures of lupus nephritis activity was evaluated by Bauer
and colleagues [25]. Thirty patients were classified as having
high or low IFN gene scores (15 patients each) and the
association with lupus disease activity indices or other clinical
features was determined. High IFN scores were positively
associated with increased disease activity as indicated by the
SLEDAI and the Systemic Lupus Activity Measure – Revised
but not by the BILAG or physician global assessment.
Immunologic manifestations and decreased C3 were also
associated with high IFN signatures. Similarly, Kirou and
colleagues, also found significant correlations between IFN
scores, the SLEDAI 2000 immunologic manifestations, and
decreased C3 [26]. In addition, this group also identified
significant associations between renal involvement and
autoantibody profiles.
Similar associations between disease activity scores and IFN
scores have been found in all studies that examined them.
Importantly, one study also demonstrated that treatment of
lupus patients with high-dose steroids rapidly extinguished
the IFN gene signature, suggesting that this biomarker may
be useful for the evaluation of therapeutic response in clinical
studies [19]. The expression of sialic acid binding immuno-
globulin-like lectin 1 (Siglec-1) on circulating blood mono-
cytes was very recently shown to be a reflection of the type I
IFN signature and a potential biomarker for monitoring
disease activity. Siglec-1 cell surface expression correlated
with the SLEDAI and the anti-DNA level, and was inversely
correlated with complement C3 [27].
Additional longitudinal studies of the response of the IFN
gene signature to standard and experimental therapies are
essential before this biomarker can be validated as a
predictor of clinical response. At least one pharmaceutical
company is applying the IFN signature as a rapid indicator of
clinical response in early phase I/II trials targeting IFNα by a
monoclonal antibody [28]. Notably, the Medimmune group
recruited only patients with mild to moderate disease activity
and specifically excluded patients with active renal disease.
Their study demonstrated that the elevated IFN signature is a
characteristic of approximately 60% (37 out of 62) of
subjects in this population. Furthermore, the presence of IFN-
inducible proteins could be detected in skin biopsies of
lesional tissue. If these results can be replicated in larger
studies, it would provide strong evidence that IFN-driven
disease activity is not confined solely to patients with the
most severe disease (that is, lupus nephritis), but is a
common characteristic of approximately one-half of lupus
patients. This of course raises the important question of
which biomarkers may define the other 50% of patients.
Interferon-regulated chemokines
Given the association of the IFN-responsive gene signature
described above with lupus nephritis, it is perhaps not
surprising that a protein correlate of this activity can be found
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used a multiplex serum protein analysis to measure the levels
of 160 different proteins in the serum of lupus patients and of
healthy control subjects [25]. From this original panel, 30
analytes were identified that were dysregulated in lupus
nephritis patients – 12 of which were determined by in vitro
studies to be IFN regulated. Notably, CD25 was also part of
this serum signature. As with the IFN gene signature, the
composite chemokine protein score positively correlated with
the SLEDAI, with the Systemic Lupus Activity Measure –
Revised, and with anti-dsDNA antibodies. Lupus patients in
this study were also grouped according to the IFN gene
signature score (high vs. low), and the cytokine/chemokine
profiles between the IFN high and IFN low groups were
demonstrated to be remarkably similar and both were very
distinct from healthy controls. When correlations between
individual chemokines and specific organ manifestations were
examined, there appeared to be differences in the serum
chemokine profiles between the different groups. In
particular, it is interesting to note that there was actually a
negative correlation of chemokine levels to the presence of
hematological manifestations (predominantly thrombocyto-
penia). Although sample sizes in this study were very small
(n = 7 for hematologic samples), this finding is nevertheless
very intriguing – and if confirmed in larger studies, may
provide additional means for stratifying patients to potential
new therapeutic candidates.
A follow-up to this study was reported in an abstract
presented at the 2008 American College of Rheumatology
meeting [29]. Specific immunoassays were used to quanti-
tate serum levels of IP-10, MCP-1, and MIP-3β in a
longitudinal study of 222 patients over 1 year (~1,300 visits).
Detailed clinical and laboratory measurements indicated that
measurements of serum chemokine levels, in particular IP-10,
outperformed standard laboratory tests (anti-dsDNA anti-
bodies and complement levels) as indicators of current
disease activity. Furthermore, baseline chemokine levels were
also good predictors of future disease course. Further studies
on the response of chemokine score to therapeutic inter-
vention will be essential for validating this approach for use in
decision-making within clinical studies.
Additional promising biomarkers
The list of serum proteins and leukocyte activation markers
that are found elevated in the blood of lupus patients has
been rapidly expanding in recent years. Many of these
molecules are now emerging as potential therapeutic targets.
From a translational medicine perspective, several molecules
are also showing promise as biomarkers of lupus disease
activity.
Soluble IL-2 receptor
Expression of the IL-2 receptor is upregulated on T cells
during activation and the soluble form is released as a result
of proteolytic cleavage. Although a precise biological role for
soluble IL-2 receptor (sCD25) is unclear, its levels are largely
viewed as an indicator of lymphocyte activation, and therefore
may not be specific for SLE. Increased levels of sCD25 in
serum of SLE patients have been described for 20 years
[30-32]. In addition, soluble forms of CD27 and CD40 ligand
have also been detected in serum from lupus patients
[33,34]. While most studies have demonstrated a positive
correlation between levels of sCD25 and disease activity,
longitudinal studies have also supported its use as a
biomarker that is closely correlated with flare activity and
therapeutic responses, particularly in patients with renal
involvement [35,36]. sCD25 does not, however, appear to be
a highly responsive marker in patients with moderate disease
or mild flare.
In total, the results of studies into the association of sCD25
with lupus disease activity strongly support the inclusion of
this protein as part of a biomarker panel. As with the
measurement of complement activation, however, its utility
may be limited to studies of patients with high disease
activity.
B-cell activating factor of the TNF family
B-cell activating factor of the TNF family (BAFF) is a cytokine
belonging to the TNF superfamily, and is a B-cell activator
that controls peripheral B-cell maturation. BAFF (also known
as BLys) stimulates B-cell proliferation and is necessary for
B-cell survival. Transgenic overexpression of BAFF in mice
results in abnormally high B-cell numbers and in the develop-
ment of a lupus-like disease [37]. This observation suggested
a role for BAFF in SLE and was further evaluated in patients.
Serum levels of BAFF and BAFF mRNA in peripheral
leukocytes are found to be elevated in lupus patients and are
positively associated with disease activity indices [38-41]. Of
note, BAFF levels tend to fluctuate during the natural course
of SLE and appear to be associated with anti-dsDNA
antibodies [42]. In addition, BAFF production is apparently
influenced/controlled by type I IFNs, as has been suggested
by recent studies in AIRE–/– mice [43]. There could therefore
be a possibility that enhanced BAFF levels are the result of
increased IFN production in SLE and these cytokines are
rather interrelated rather than independently enhanced.
Interestingly, one-half of lupus patients show enhanced
serum BAFF levels, whereas the remaining patients do not
show increased BAFF levels. One study demonstrated a
close relationship between mRNA levels of BAFF and
disease activity, which however, was not identified for the
protein levels of BAFF [44]. Additionally, BAFF levels were
also identified to correlate with the severity and therapeutic
response in autoimmune thrombocytopenia, suggesting its
value as biomarker in this entity [45].
CD40 ligand expression
The expression of costimulatory molecule CD40 ligand,
which was previously identified as a biomarker for lupus
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on peripheral T cells from lupus patients and normalized
following rituximab treatment [46]. Notably, downregulation of
CD40 ligand expression preceded clinical response, as early
as 1 month following treatment. These data point towards
CD40 ligand being a potential sensitive biomarker of activity
and response to treatment.
Inducible costimulator expression
The inducible costimulator (ICOS) is a member of the CD28
family that, like CD28, can enhance T-cell proliferation and
cytokine secretion. In the first study in human SLE, Hutloff
and colleagues demonstrated overexpression of ICOS on
CD4+ and CD8+ T cells and a remarkable reduction of ICOS
ligand on CD27+ memory B cells [47]. In addition, lupus
nephritis patients had an accumulation of germinal center-like
structures in their kidneys. These data suggested that there is
continuous crosstalk and activation between T cells and B
cells in SLE, leading to the overactivation of the adaptive
immunity in lupus.
In confirmation, Yang and colleagues investigated the
expression of ICOS on CD4 and CD8 T cells from lupus
patients [48] in peripheral blood from moderately and highly
active SLE patients. They found elevated numbers of ICOS-
positive T cells, both CD4 and CD8, as well as elevated
levels of ICOS expression compared with healthy controls or
rheumatoid arthritis patients. Furthermore, longitudinal analy-
sis of individual patients indicated that ICOS was significantly
elevated during the active phase when compared with clinical
remission.
Sialic acid binding immunoglobulin-like lectin 1
Siglec-1 (sialoadhesin, CD169) is a macrophage-restricted
receptor that interacts with surface molecules on a number of
other cell types, including B cells and T cells [49,50]. Biesen
and colleagues recently identified Siglec-1 as a highly
upregulated gene expressed by peripheral blood monocytes
from lupus and systemic sclerosis patients, but not in
rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis
[27]. Importantly, Siglec-1 surface expression, as analyzed by
fluorescence-activated cell sorting, was positively correlated
with the SLEDAI and ant-dsDNA while being negatively
correlated with C3 levels – indicating that this expression of
this novel marker closely parallels traditional disease activity
measures. Furthermore, treatment of four patients with
intravenous pulse glucocorticoids resulted in a decrease in
Siglec-1-positive monocytes from 77% to 12% within 7 days,
suggesting that this may be a useful biomarker for the
assessment of clinical response to novel therapeutics.
CD27high plasma cells and peripheral B-cell subset analysis
B cells can be subdivided along the developmental and
activation pathway according to the presence or absence of a
variety of cell surface molecules. Abnormalities in B-cell
subsets in lupus patients have been described in a number of
studies. Notably, the expansion of a unique population of
CD19+/CD27high plasma cells was noted under the condition
of lupus. Jacobi and colleagues evaluated the correlation of
CD27high plasma cells and disease activity in lupus patients
[51]. Patients with high disease activity (SLEDAI >8) had
significantly increased frequency of CD19+/CD27high plasma
cells and had a predictive value for disease activity that was
greater than traditional humoral/clinical measurements (for
example, anti-dsDNA, complement, renal manifestations). In
addition, there was a statistically significant correlation
between these plasma cells with the SLEDAI as well as with
the anti-DNA titers. Interestingly, the CD27high cells also
correlated with the SLEDAI as measurement of the disease
activity in SLE in patients not producing anti-dsDNA
autoantibodies. More recent data show that a particular
CD27–/IgD– B-cell subset is expanded in SLE [52,53]. Only
the CD27–/IgD–/CD95+ B cells, however, are uniquely
expanded in lupus patients, display a memory phenotype, and
correlate with lupus activity.
Together, these analyses suggest that monitoring peripheral
B cells using CD27 expression may be a reliable biomarker of
lupus disease activity and clinical response, but needs to be
evaluated in larger trials.
Conclusions
The path to new therapeutics for lupus has been littered with
many failed clinical studies, although very recently the phase
III trials BLISS-52 and BLISS-76 using belimumab and a
phase IIb trial using epratuzumab (both only announced by
press releases) could demonstrate effects superior to
placebo. The question remains, however, whether the
previously failed drug candidates had the wrong target or just
a suboptimal study design.
Given the heterogeneity of this disease, we propose that
clinical trial design needs to be refocused to take into con-
sideration recruiting patients based upon an immunological
characterization of the patient with emphasis on relevance to
the mechanism of action of the test compound. Such a
characterization might include autoantibody profiles, gene
signatures, serum proteins, and leukocyte surface markers.
For such an approach to be successful, however, well-
validated biomarkers are essential. As described above,
several novel biomarker strategies have emerged from the
literature in recent years, although to date none have been
studied in enough detail to be useful in decision-making
within clinical trials. In order for a biomarker to be qualified for
use in decision-making, epidemiologic or observational
studies of the natural history of the disease should establish
the relationship between the biomarker, defined clinical
cohorts as already widely used for lupus nephritis, and
defined clinical endpoints.
To date, the vast majority of biomarker studies in lupus have
attempted to link clinical activity to only one, or a few,
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is lupus really one disease? – a multiplexed approach is
clearly going to be essential. Biomarker validation is an
iterative process requiring multiple studies to identify,
characterize, and confirm the validity of the biomarker for the
intended purpose. Pharmaceutical companies and clinical
trialists need to commit to the evaluation of multiple,
exploratory biomarkers within clinical studies and to sharing
of the information if we are to improve our understanding of
lupus and the response to active therapies. It is a long-term
investment but one that the lupus community has recognized
and is embracing as the critical path to a successful lupus
therapy.
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